Search Results

Revvity Signals handles all software development, allowing researchers to explore new drug therapies. Learn how our cloud-native software helps with performance, cost and scalability.

In 2024, Signals ChemDraw, Signals Clinical and Signals Synergy launched. Read how Revvity Signals supports new modalities in drug discovery and research development.

Nexus 2021 Day Two Recap: Empowering Data-Driven Science with Flexible Informatics Day Two of Revvity Signal's Nexus 2021 Informatics Virtual User Conference delivered another engaging slate of presenters – from Merck KGaA, Birla Carbon and Givaudan to Bayer, Nimbus Therapeutics and Johnson & Johnson. If you’ve registered but missed a session (or even a day...

Revvity Signals was first-to-market with SaaS software and integrates AI to help empower scientists. Read our interview with David Gosalvez to learn the future vision of Revvity Signals.

Revvity introduces groundbreaking Phenologic.AI software at SLAS 2025, transforming cellular imaging workflows and showcasing innovative life sciences solutions for drug discovery and development.

Explore Revvity Signals’ 2025 Year in Review, highlighting major advances in AI-driven discovery, unified R&D data platforms, and new capabilities across Signals One.